DU-176b 15mg + DU-176b 30mg + DU-176b 60mg
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-valvular Atrial Fibrillation
Conditions
Non-valvular Atrial Fibrillation
Trial Timeline
Nov 1, 2011 → Jan 1, 2013
NCT ID
NCT01857622About DU-176b 15mg + DU-176b 30mg + DU-176b 60mg
DU-176b 15mg + DU-176b 30mg + DU-176b 60mg is a phase 3 stage product being developed by Daiichi Sankyo for Non-valvular Atrial Fibrillation. The current trial status is completed. This product is registered under clinical trial identifier NCT01857622. Target conditions include Non-valvular Atrial Fibrillation.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01857622 | Phase 3 | Completed |
Competing Products
17 competing products in Non-valvular Atrial Fibrillation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Edoxaban | Daiichi Sankyo | Pre-clinical | 23 |
| Edoxaban + Aspirin and Clopidogrel + Aspirin and Warfarin | Daiichi Sankyo | Approved | 85 |
| Edoxaban | Daiichi Sankyo | Pre-clinical | 23 |
| AZD0837 + Aspirin | AstraZeneca | Phase 2 | 52 |
| Apixaban + Warfarin | Pfizer | Pre-clinical | 22 |
| Warfarin + Apixaban | Pfizer | Pre-clinical | 22 |
| Apixaban | Bristol Myers Squibb | Approved | 84 |
| Apixaban | Bristol Myers Squibb | Pre-clinical | 22 |
| Rivaroxaban (Xarelto, BAY59-7939) | Bayer | Pre-clinical | 20 |
| Rivaroxaban(Xarelto,BAY 59-7939) | Bayer | Pre-clinical | 20 |
| Rivaroxaban (Xarelto,Bay 59-7939) | Bayer | Pre-clinical | 20 |
| Rivaroxaban (Xarelto, BAY59-7939) + Warfarin | Bayer | Pre-clinical | 20 |
| Rivaroxaban (Xarelto, BAY-597939) + VKAs | Bayer | Pre-clinical | 20 |
| Non-VKA Oral Anticoagulants (NOAC) | Bayer | Pre-clinical | 20 |
| Rivaroxaban (Xarelto, BAY59-7939) | Bayer | Pre-clinical | 20 |
| Rivaroxaban (Xarelto_ BAY59-7939) | Bayer | Pre-clinical | 20 |
| Rivaroxaban (Xarelto, BAY59-7939) + Apixaban (Eliquis) + Dabigatran etexilate (Pradaxa) + Warfarin (Marevan) | Bayer | Pre-clinical | 20 |